Clinical Trial Update: Platelet Inhibition of Ticagrelor Versus Clopidogrel in Type 2 Diabetic Patients After Elective Percutaneous Coronary Intervention [Phase 4]

View source ↗

Summary

A Phase 4 trial comparing ticagrelor to clopidogrel for platelet inhibition in type 2 diabetes patients after elective PCI has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease
• Type 2 Diabetes Mellitus

Drugs mentioned

• CLOPIDOGREL (CLOPIDOGREL)
• TICAGRELOR (ticagrelor)

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Coronary Artery Disease, Diabetes Mellitus, Type 2 | Phase 4 | Status: COMPLETED